Every 10-Q that Sight Sciences, Inc. (SGHT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SGHT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGHT filings page.
Sight Sciences reported Q2 2026 revenue of $23.4 million, up 19.5% year over year, and first‑half revenue of $43.1 million. Gross margin improved to 91.4% in the quarter, supported by tariff refunds and higher average selling prices. Net loss narrowed to $4.4 million in Q2 and $17.4 million year‑to‑date.
Interventional Glaucoma contributed $20.7 million of Q2 revenue, while Interventional Dry Eye grew to $2.7 million as Medicare fee schedules for the TearCare procedure drove higher volume. Cash and cash equivalents were $79.8 million against $40.0 million of term loans at a 10.35% rate; operating cash outflow was $12.7 million for the first half. A Delaware federal court entered judgment awarding $55.4 million in patent damages and a 10% ongoing royalty on Hydrus Microstent revenue, though Alcon has appealed and two related USPTO ex parte reexaminations remain pending. Management believes existing liquidity will fund at least the next 12 months while it continues commercialization and R&D at reduced spending levels.
Sight Sciences, Inc. reported first-quarter 2026 revenue of $19.7 million, up 12.5% from $17.5 million a year earlier, driven by growth in both glaucoma and dry eye products. Net loss narrowed to $13.0 million from $14.2 million as higher gross profit offset increased legal costs.
Interventional Glaucoma revenue rose to $18.3 million, while Interventional Dry Eye revenue increased to $1.4 million after new reimbursement support. Gross margin held at 86.2%. The company ended the quarter with $85.0 million in cash and cash equivalents and $40.0 million of term loan principal outstanding.
A Delaware federal court’s final judgment in the Alcon litigation awarded $55.4 million in damages and a 10% ongoing royalty on Hydrus revenue, and triggered a $5.4 million litigation success fee, while related patent reexaminations at the USPTO continue.
Sight Sciences (SGHT) reported Q3 2025 results with revenue of $19.9 million, slightly lower than $20.2 million a year ago, as Surgical Glaucoma held steady and Dry Eye remained soft. Gross profit was $17.2 million while operating expenses fell to $25.1 million, narrowing the net loss to $8.2 million from $11.1 million. For the nine months, revenue was $57.0 million and net loss was $34.3 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, down from $120.4 million at year-end, reflecting operating cash outflows. Long-term debt stood at $40.1 million. The company amended its Hercules loan in September, extending the interest-only period to February 1, 2027 and increasing potential incremental tranches (subject to lender approval) while maintaining the $65 million facility.
Management executed a targeted restructuring in Q3, recording $2.8 million of charges to reduce operating expenses. Subsequent to quarter-end, two Medicare Administrative Contractors set jurisdiction-wide pricing for CPT 0563T tied to TearCare, effective retroactive to January 1, 2025. A prior $34 million jury verdict in patent litigation awaits judgment and may be affected by USPTO reexaminations.